NR2F1

Across TCGA pan-cancer cohorts, NR2F1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NR2F1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NR2F1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NR2F1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, OV, and UCEC are the cancer types where NR2F1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.110	0.681	<.001	26	view →
OV	DFS	Median	II,III,IV	0.204	0.541	.017	12	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SKCM	DFS	Median	III,IV	0.814	0.244	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NR2F1–ACC (DFS)

Open the ACC breakdown →